Use of Buprenorphine in treatment of refractory depression—A review of current literature
| Autor: | Oliver M. Glass, Cornel N. Stanciu, Thomas M. Penders |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Controlled studies Unmet needs law.invention Depressive Disorder Treatment-Resistant 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Randomized controlled trial law medicine Humans Psychiatry General Psychology business.industry General Medicine medicine.disease Antidepressive Agents Buprenorphine 030227 psychiatry Analgesics Opioid Psychiatry and Mental health Treatment Outcome Mood Opioid business Treatment-resistant depression 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Asian Journal of Psychiatry. 26:94-98 |
| ISSN: | 1876-2018 |
| Popis: | Objective Current treatment strategies for depressive disorders have limited efficacy, leaving many patients unimproved or with significant residual symptoms. The development of additional treatments represent a significant unmet need for providers. Several lines of evidence suggest that the opioid system may be involved in regulation of mood and incentives salience. Intervention based on modifying central opioid receptors may represent a novel approach to treatment of depressive disorders among those unresponsive to accepted treatments. Data sources We searched the English language literature using keywords: Buprenorphine AND Major Depression; Buprenorphine AND Bipolar Depression; Buprenorphine AND Affective Disorders. Results Use of low dose buprenorphine as augmentation of pharmacotherapy for depression has shown promise in several reported studies. Effect size of available randomized controlled studies is comparable if not greater than most accepted augmentation strategies. Conclusion Review of available literature on the use of buprenorphine in individuals with treatment resistant depression demonstrated efficacy in the treatment of depressive disorders. Further prospective randomized controlled trials should be undertaken to evaluate the efficacy of buprenorphine as an adjunct for depression refractory to current pharmacotherapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect